IgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal study
An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4 ) B cells and plasma cells are implicated in the pathogenesis of GPA. We hypothesized that the presence of these cells in peripheral blood could serve as diseas...
Saved in:
| Published in | Arthritis research & therapy Vol. 21; no. 1; pp. 43 - 11 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
31.01.2019
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4
) B cells and plasma cells are implicated in the pathogenesis of GPA. We hypothesized that the presence of these cells in peripheral blood could serve as disease activity parameter in GPA.
We included 35 proteinase 3-antineutrophil cytoplasmic antibodies-positive patients with GPA in a cross-sectional study. Active disease was defined as Birmingham Vasculitis Activity Score (BVAS) ≥ 3 (n = 15), remission as BVAS of 0 (n = 17), and low disease activity (LDA) as BVAS of 1-2 and clinical remission (n = 3). Healthy subjects (n = 10), patients with systemic lupus erythematosus (n = 24), and patients with rheumatoid arthritis (n = 19) functioned as control subjects. An additional longitudinal study was performed in ten patients with GPA. Using a validated qPCR test, we measured the IgG4:IgG RNA ratio in all groups and compared the results with known biomarkers.
The median qPCR score was higher in active GPA (21.4; IQR 12.1-29.6) than in remission/LDA (3.3; IQR 1.6-5.6) (Mann-Whitney U test, p < 0.0001) and outperformed other known disease activity parameters in detecting activity. A cutoff qPCR score of 11.2% differentiated active disease from remission/LDA accurately (AUC 0.993). The qPCR test correlated well with the BVAS (Spearman r = 0.77, p < 0.0001). In the longitudinal study, a decrease in BVAS correlated with qPCR score reduction (paired t test, p < 0.05).
The IgG4:IgG RNA ratio in GPA accurately distinguishes active disease from remission and correlates well with disease activity in these single-center studies. If these results are confirmed in larger longitudinal studies, this test might help to steer treatment decisions in patients with GPA. |
|---|---|
| AbstractList | An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4+) B cells and plasma cells are implicated in the pathogenesis of GPA. We hypothesized that the presence of these cells in peripheral blood could serve as disease activity parameter in GPA.OBJECTIVESAn important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4+) B cells and plasma cells are implicated in the pathogenesis of GPA. We hypothesized that the presence of these cells in peripheral blood could serve as disease activity parameter in GPA.We included 35 proteinase 3-antineutrophil cytoplasmic antibodies-positive patients with GPA in a cross-sectional study. Active disease was defined as Birmingham Vasculitis Activity Score (BVAS) ≥ 3 (n = 15), remission as BVAS of 0 (n = 17), and low disease activity (LDA) as BVAS of 1-2 and clinical remission (n = 3). Healthy subjects (n = 10), patients with systemic lupus erythematosus (n = 24), and patients with rheumatoid arthritis (n = 19) functioned as control subjects. An additional longitudinal study was performed in ten patients with GPA. Using a validated qPCR test, we measured the IgG4:IgG RNA ratio in all groups and compared the results with known biomarkers.METHODSWe included 35 proteinase 3-antineutrophil cytoplasmic antibodies-positive patients with GPA in a cross-sectional study. Active disease was defined as Birmingham Vasculitis Activity Score (BVAS) ≥ 3 (n = 15), remission as BVAS of 0 (n = 17), and low disease activity (LDA) as BVAS of 1-2 and clinical remission (n = 3). Healthy subjects (n = 10), patients with systemic lupus erythematosus (n = 24), and patients with rheumatoid arthritis (n = 19) functioned as control subjects. An additional longitudinal study was performed in ten patients with GPA. Using a validated qPCR test, we measured the IgG4:IgG RNA ratio in all groups and compared the results with known biomarkers.The median qPCR score was higher in active GPA (21.4; IQR 12.1-29.6) than in remission/LDA (3.3; IQR 1.6-5.6) (Mann-Whitney U test, p < 0.0001) and outperformed other known disease activity parameters in detecting activity. A cutoff qPCR score of 11.2% differentiated active disease from remission/LDA accurately (AUC 0.993). The qPCR test correlated well with the BVAS (Spearman r = 0.77, p < 0.0001). In the longitudinal study, a decrease in BVAS correlated with qPCR score reduction (paired t test, p < 0.05).RESULTSThe median qPCR score was higher in active GPA (21.4; IQR 12.1-29.6) than in remission/LDA (3.3; IQR 1.6-5.6) (Mann-Whitney U test, p < 0.0001) and outperformed other known disease activity parameters in detecting activity. A cutoff qPCR score of 11.2% differentiated active disease from remission/LDA accurately (AUC 0.993). The qPCR test correlated well with the BVAS (Spearman r = 0.77, p < 0.0001). In the longitudinal study, a decrease in BVAS correlated with qPCR score reduction (paired t test, p < 0.05).The IgG4:IgG RNA ratio in GPA accurately distinguishes active disease from remission and correlates well with disease activity in these single-center studies. If these results are confirmed in larger longitudinal studies, this test might help to steer treatment decisions in patients with GPA.CONCLUSIONSThe IgG4:IgG RNA ratio in GPA accurately distinguishes active disease from remission and correlates well with disease activity in these single-center studies. If these results are confirmed in larger longitudinal studies, this test might help to steer treatment decisions in patients with GPA. Objectives An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4.sup.+) B cells and plasma cells are implicated in the pathogenesis of GPA. We hypothesized that the presence of these cells in peripheral blood could serve as disease activity parameter in GPA. Methods We included 35 proteinase 3-antineutrophil cytoplasmic antibodies-positive patients with GPA in a cross-sectional study. Active disease was defined as Birmingham Vasculitis Activity Score (BVAS) [greater than or equai to] 3 (n = 15), remission as BVAS of 0 (n = 17), and low disease activity (LDA) as BVAS of 1-2 and clinical remission (n = 3). Healthy subjects (n = 10), patients with systemic lupus erythematosus (n = 24), and patients with rheumatoid arthritis (n = 19) functioned as control subjects. An additional longitudinal study was performed in ten patients with GPA. Using a validated qPCR test, we measured the IgG4:IgG RNA ratio in all groups and compared the results with known biomarkers. Results The median qPCR score was higher in active GPA (21.4; IQR 12.1-29.6) than in remission/LDA (3.3; IQR 1.6-5.6) (Mann-Whitney U test, p < 0.0001) and outperformed other known disease activity parameters in detecting activity. A cutoff qPCR score of 11.2% differentiated active disease from remission/LDA accurately (AUC 0.993). The qPCR test correlated well with the BVAS (Spearman r = 0.77, p < 0.0001). In the longitudinal study, a decrease in BVAS correlated with qPCR score reduction (paired t test, p < 0.05). Conclusions The IgG4:IgG RNA ratio in GPA accurately distinguishes active disease from remission and correlates well with disease activity in these single-center studies. If these results are confirmed in larger longitudinal studies, this test might help to steer treatment decisions in patients with GPA. Keywords: Granulomatosis with polyangiitis, Biomarkers, Immunoglobulin G4, Disease activity, Quantitative polymerase chain reaction Abstract Objectives An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4+) B cells and plasma cells are implicated in the pathogenesis of GPA. We hypothesized that the presence of these cells in peripheral blood could serve as disease activity parameter in GPA. Methods We included 35 proteinase 3-antineutrophil cytoplasmic antibodies-positive patients with GPA in a cross-sectional study. Active disease was defined as Birmingham Vasculitis Activity Score (BVAS) ≥ 3 (n = 15), remission as BVAS of 0 (n = 17), and low disease activity (LDA) as BVAS of 1–2 and clinical remission (n = 3). Healthy subjects (n = 10), patients with systemic lupus erythematosus (n = 24), and patients with rheumatoid arthritis (n = 19) functioned as control subjects. An additional longitudinal study was performed in ten patients with GPA. Using a validated qPCR test, we measured the IgG4:IgG RNA ratio in all groups and compared the results with known biomarkers. Results The median qPCR score was higher in active GPA (21.4; IQR 12.1–29.6) than in remission/LDA (3.3; IQR 1.6–5.6) (Mann-Whitney U test, p < 0.0001) and outperformed other known disease activity parameters in detecting activity. A cutoff qPCR score of 11.2% differentiated active disease from remission/LDA accurately (AUC 0.993). The qPCR test correlated well with the BVAS (Spearman r = 0.77, p < 0.0001). In the longitudinal study, a decrease in BVAS correlated with qPCR score reduction (paired t test, p < 0.05). Conclusions The IgG4:IgG RNA ratio in GPA accurately distinguishes active disease from remission and correlates well with disease activity in these single-center studies. If these results are confirmed in larger longitudinal studies, this test might help to steer treatment decisions in patients with GPA. An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4.sup.+) B cells and plasma cells are implicated in the pathogenesis of GPA. We hypothesized that the presence of these cells in peripheral blood could serve as disease activity parameter in GPA. We included 35 proteinase 3-antineutrophil cytoplasmic antibodies-positive patients with GPA in a cross-sectional study. Active disease was defined as Birmingham Vasculitis Activity Score (BVAS) [greater than or equai to] 3 (n = 15), remission as BVAS of 0 (n = 17), and low disease activity (LDA) as BVAS of 1-2 and clinical remission (n = 3). Healthy subjects (n = 10), patients with systemic lupus erythematosus (n = 24), and patients with rheumatoid arthritis (n = 19) functioned as control subjects. An additional longitudinal study was performed in ten patients with GPA. Using a validated qPCR test, we measured the IgG4:IgG RNA ratio in all groups and compared the results with known biomarkers. The median qPCR score was higher in active GPA (21.4; IQR 12.1-29.6) than in remission/LDA (3.3; IQR 1.6-5.6) (Mann-Whitney U test, p < 0.0001) and outperformed other known disease activity parameters in detecting activity. A cutoff qPCR score of 11.2% differentiated active disease from remission/LDA accurately (AUC 0.993). The qPCR test correlated well with the BVAS (Spearman r = 0.77, p < 0.0001). In the longitudinal study, a decrease in BVAS correlated with qPCR score reduction (paired t test, p < 0.05). The IgG4:IgG RNA ratio in GPA accurately distinguishes active disease from remission and correlates well with disease activity in these single-center studies. If these results are confirmed in larger longitudinal studies, this test might help to steer treatment decisions in patients with GPA. Objectives An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4+) B cells and plasma cells are implicated in the pathogenesis of GPA. We hypothesized that the presence of these cells in peripheral blood could serve as disease activity parameter in GPA. Methods We included 35 proteinase 3-antineutrophil cytoplasmic antibodies-positive patients with GPA in a cross-sectional study. Active disease was defined as Birmingham Vasculitis Activity Score (BVAS) ≥ 3 (n = 15), remission as BVAS of 0 (n = 17), and low disease activity (LDA) as BVAS of 1–2 and clinical remission (n = 3). Healthy subjects (n = 10), patients with systemic lupus erythematosus (n = 24), and patients with rheumatoid arthritis (n = 19) functioned as control subjects. An additional longitudinal study was performed in ten patients with GPA. Using a validated qPCR test, we measured the IgG4:IgG RNA ratio in all groups and compared the results with known biomarkers. Results The median qPCR score was higher in active GPA (21.4; IQR 12.1–29.6) than in remission/LDA (3.3; IQR 1.6–5.6) (Mann-Whitney U test, p < 0.0001) and outperformed other known disease activity parameters in detecting activity. A cutoff qPCR score of 11.2% differentiated active disease from remission/LDA accurately (AUC 0.993). The qPCR test correlated well with the BVAS (Spearman r = 0.77, p < 0.0001). In the longitudinal study, a decrease in BVAS correlated with qPCR score reduction (paired t test, p < 0.05). Conclusions The IgG4:IgG RNA ratio in GPA accurately distinguishes active disease from remission and correlates well with disease activity in these single-center studies. If these results are confirmed in larger longitudinal studies, this test might help to steer treatment decisions in patients with GPA. An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4 ) B cells and plasma cells are implicated in the pathogenesis of GPA. We hypothesized that the presence of these cells in peripheral blood could serve as disease activity parameter in GPA. We included 35 proteinase 3-antineutrophil cytoplasmic antibodies-positive patients with GPA in a cross-sectional study. Active disease was defined as Birmingham Vasculitis Activity Score (BVAS) ≥ 3 (n = 15), remission as BVAS of 0 (n = 17), and low disease activity (LDA) as BVAS of 1-2 and clinical remission (n = 3). Healthy subjects (n = 10), patients with systemic lupus erythematosus (n = 24), and patients with rheumatoid arthritis (n = 19) functioned as control subjects. An additional longitudinal study was performed in ten patients with GPA. Using a validated qPCR test, we measured the IgG4:IgG RNA ratio in all groups and compared the results with known biomarkers. The median qPCR score was higher in active GPA (21.4; IQR 12.1-29.6) than in remission/LDA (3.3; IQR 1.6-5.6) (Mann-Whitney U test, p < 0.0001) and outperformed other known disease activity parameters in detecting activity. A cutoff qPCR score of 11.2% differentiated active disease from remission/LDA accurately (AUC 0.993). The qPCR test correlated well with the BVAS (Spearman r = 0.77, p < 0.0001). In the longitudinal study, a decrease in BVAS correlated with qPCR score reduction (paired t test, p < 0.05). The IgG4:IgG RNA ratio in GPA accurately distinguishes active disease from remission and correlates well with disease activity in these single-center studies. If these results are confirmed in larger longitudinal studies, this test might help to steer treatment decisions in patients with GPA. |
| ArticleNumber | 43 |
| Audience | Academic |
| Author | Tas, S. W. de Vries, N. Klarenbeek, P. L. Doorenspleet, M. E. Burgemeister, L. T. Al-Soudi, A. van Vollenhoven, R. F. Hak, A. E. van den Born, B. J. H. Esveldt, R. E. |
| Author_xml | – sequence: 1 givenname: A. orcidid: 0000-0002-3920-4022 surname: Al-Soudi fullname: Al-Soudi, A. – sequence: 2 givenname: M. E. surname: Doorenspleet fullname: Doorenspleet, M. E. – sequence: 3 givenname: R. E. surname: Esveldt fullname: Esveldt, R. E. – sequence: 4 givenname: L. T. surname: Burgemeister fullname: Burgemeister, L. T. – sequence: 5 givenname: A. E. surname: Hak fullname: Hak, A. E. – sequence: 6 givenname: B. J. H. surname: van den Born fullname: van den Born, B. J. H. – sequence: 7 givenname: S. W. surname: Tas fullname: Tas, S. W. – sequence: 8 givenname: R. F. surname: van Vollenhoven fullname: van Vollenhoven, R. F. – sequence: 9 givenname: P. L. surname: Klarenbeek fullname: Klarenbeek, P. L. – sequence: 10 givenname: N. surname: de Vries fullname: de Vries, N. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30704507$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kl1rFDEUhgep2Hb1B3gjAW-8mZpMvmZ6oSxF60JREL0O2XxMs84mNcm07H_yR5rZbctuUQKTcPKe58w5eU-rIx-8qarXCJ4h1LL3CWHIaQ1RW6MWspo9q04Q4W3NMGuO9s7H1WlKKwibpmvIi-q4pEFCIT-p_iz6S3JePuD71zmIMrsAtLPWROOzk9kkIFV2t6ZEk5HJABvDGkSzdim54IHzoI_Sj0NYyxySS-DO5WtwE4aN9L1z2aVzIIE3d4-ELdDlDVjL-MvEj2AOVAwp1cmUm-DlAKTXYAglP4_aTYFUDpuX1XMrh2Re3e-z6ufnTz8uvtRX3y4XF_OrWlEGc4261mAr6RLpDnOstaSUcs3xErdLSDpIOZSd4hxp3DSWwKY1jcTIdgS3hGk8qxY7rg5yJW6iKz-6EUE6sQ2E2AsZs1ODER23CktDuYWMWK4kWxKlWAO1UhzqtrA-7Fg343JttCpjjXI4gB7eeHct-nArGKacYFwA7-4BMfweTcqijF6ZYZDehDGJBvGOcAzhVOvtE-kqjLGMb1K1GFLW7qt6WRpw3oZSV01QMactwqTU7Yrq7B-qsnR5elV8aF2JHyS82W_0scMHrxUB3wm2jx2NFcrlyXBT324QCIrJ1WLnalFcLSZXl0HMKvQk8wH-_5y_qK_67Q |
| CitedBy_id | crossref_primary_10_1186_s13075_024_03448_w crossref_primary_10_1007_s00296_023_05419_x crossref_primary_10_3389_fimmu_2021_571933 crossref_primary_10_1097_IOP_0000000000002187 crossref_primary_10_1016_j_rmcr_2021_101451 crossref_primary_10_1111_1756_185X_13768 crossref_primary_10_47360_1995_4484_2020_550_559 crossref_primary_10_3390_ijms23010387 crossref_primary_10_1016_j_autrev_2020_102646 |
| Cites_doi | 10.1002/art.11075 10.1093/rheumatology/ker280 10.1155/2012/121702 10.3109/03009742.2014.905628 10.1073/pnas.1313944110 10.2169/internalmedicine.49.3532 10.1681/ASN.2014010046 10.2169/internalmedicine.51.7725 10.1111/j.1365-2249.1991.tb05647.x 10.1016/j.semarthrit.2015.07.009 10.1016/j.autrev.2013.11.003 10.1097/MD.0000000000004633 10.2169/internalmedicine.51.6074 10.1136/annrheumdis-2011-200612 10.1016/S0002-9343(99)00064-9 10.1111/j.1365-2249.2004.02566.x 10.1093/brain/aws025 10.1016/j.imlet.2010.06.011 10.1136/jclinpath-2016-203875 10.1371/journal.pone.0156800 10.1007/s11882-016-0621-x 10.1021/ja203638y 10.1007/s11926-013-0348-9 10.1016/S0304-3940(02)01423-4 10.1002/hep.26232 10.1046/j.0019-2805.2001.01341.x 10.1136/ard.2011.155382 10.1093/ckj/sfw056 10.1212/NXI.0000000000000341 10.1002/hep.28568 10.1016/j.humpath.2013.05.023 10.1016/j.rmcr.2017.01.001 10.4049/jimmunol.1502233 10.1093/rheumatology/kei272 10.1006/clin.1994.1007 10.3389/fimmu.2019.02221 10.1097/BOR.0000000000000009 10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5 10.1093/rheumatology/kev248 10.1007/s11102-015-0650-9 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2019 BioMed Central Ltd. Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2019 |
| Copyright_xml | – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2019 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13075-018-1806-6 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1478-6362 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_97fc3ae57f064f7ca6b4cc620dcc70d8 PMC6357433 A581345749 30704507 10_1186_s13075_018_1806_6 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: ZonMw grantid: 436001001 – fundername: Innovative Medicines Initiative grantid: ABIRISK – fundername: ; grantid: 436001001 – fundername: ; grantid: ABIRISK |
| GroupedDBID | --- .GJ 0R~ 23N 2WC 4.4 5GY 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABUWG ACGFS ACJQM ADBBV ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK E3Z EBD EBLON EJD EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE HZ~ INH INR ITC KQ8 M1P O5R O5S O9- PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SMD SOJ SV3 TR2 U2A UKHRP WOQ CGR CUY CVF ECM EIF NPM PMFND 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c560t-198e3fa5b1d9373dda5557d73b38b0490570a9c771d322f4028e2a31f943846d3 |
| IEDL.DBID | 7X7 |
| ISSN | 1478-6362 1478-6354 |
| IngestDate | Wed Aug 27 01:24:56 EDT 2025 Thu Aug 21 13:35:05 EDT 2025 Fri Jul 11 03:19:33 EDT 2025 Fri Jul 25 22:18:36 EDT 2025 Tue Jun 17 22:04:52 EDT 2025 Tue Jun 10 21:04:29 EDT 2025 Thu Apr 03 07:01:59 EDT 2025 Tue Jul 01 04:00:52 EDT 2025 Thu Apr 24 23:10:12 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Biomarkers Granulomatosis with polyangiitis Immunoglobulin G4 Disease activity Quantitative polymerase chain reaction |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c560t-198e3fa5b1d9373dda5557d73b38b0490570a9c771d322f4028e2a31f943846d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-3920-4022 |
| OpenAccessLink | https://www.proquest.com/docview/2183056808?pq-origsite=%requestingapplication% |
| PMID | 30704507 |
| PQID | 2183056808 |
| PQPubID | 42876 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_97fc3ae57f064f7ca6b4cc620dcc70d8 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6357433 proquest_miscellaneous_2179473008 proquest_journals_2183056808 gale_infotracmisc_A581345749 gale_infotracacademiconefile_A581345749 pubmed_primary_30704507 crossref_citationtrail_10_1186_s13075_018_1806_6 crossref_primary_10_1186_s13075_018_1806_6 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-01-31 |
| PublicationDateYYYYMMDD | 2019-01-31 |
| PublicationDate_xml | – month: 01 year: 2019 text: 2019-01-31 day: 31 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Arthritis research & therapy |
| PublicationTitleAlternate | Arthritis Res Ther |
| PublicationYear | 2019 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | JS Sanders (1806_CR7) 2006; 45 N Ayuzawa (1806_CR23) 2012; 51 ZS Wallace (1806_CR3) 2016; 45 RC Aalberse (1806_CR33) 2016; 16 AS Lo (1806_CR38) 2016; 11 Y Qian (1806_CR39) 2016; 196 PA Monach (1806_CR5) 2014; 26 N Lomborg (1806_CR28) 2014; 43 1806_CR43 1806_CR44 SY Chang (1806_CR13) 2013; 44 C Ramakers (1806_CR22) 2003; 339 M Yamamoto (1806_CR32) 2010; 49 LH Thai (1806_CR9) 2014; 13 JH Stone (1806_CR21) 2003; 48 OJ Mellbye (1806_CR40) 1994; 70 H Touge (1806_CR29) 2017; 20 S Anwar (1806_CR1) 2017; 70 X Kyndt (1806_CR6) 1999; 106 A Kronbichler (1806_CR27) 2015; 54 ME Doorenspleet (1806_CR19) 2016; 64 SY Chang (1806_CR17) 2012; 2012 R Klooster (1806_CR37) 2012; 135 R Phillip (1806_CR2) 2008; 26 1806_CR14 J Massey (1806_CR31) 2017; 4 D Geetha (1806_CR20) 2015; 26 M Holland (1806_CR26) 2004; 138 R Perez Alamino (1806_CR15) 2013; 15 E Della-Torre (1806_CR30) 2016; 95 Y Hanioka (1806_CR25) 2012; 51 MG Huijbers (1806_CR36) 2013; 110 JB Draibe (1806_CR4) 2016; 9 MA Alba (1806_CR16) 2015; 33 LJ Maillette de Buy Wenniger (1806_CR18) 2013; 57 T Rispens (1806_CR35) 2011; 133 G Tomasson (1806_CR8) 2012; 51 RA Luqmani (1806_CR10) 1994; 87 RC Aalberse (1806_CR34) 2002; 105 H Bando (1806_CR24) 2015; 18 E Brouwer (1806_CR41) 1991; 83 1806_CR42 A Vaglio (1806_CR12) 2012; 71 JH Stone (1806_CR11) 2001; 44 |
| References_xml | – volume: 48 start-page: 2299 issue: 8 year: 2003 ident: 1806_CR21 publication-title: Arthritis Rheum doi: 10.1002/art.11075 – volume: 51 start-page: 100 issue: 1 year: 2012 ident: 1806_CR8 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/ker280 – volume: 2012 start-page: 121702 year: 2012 ident: 1806_CR17 publication-title: Int J Rheumtol doi: 10.1155/2012/121702 – volume: 43 start-page: 345 issue: 4 year: 2014 ident: 1806_CR28 publication-title: Scand J Rheumatol doi: 10.3109/03009742.2014.905628 – volume: 110 start-page: 20783 issue: 51 year: 2013 ident: 1806_CR36 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1313944110 – volume: 49 start-page: 1365 issue: 14 year: 2010 ident: 1806_CR32 publication-title: Intern Med doi: 10.2169/internalmedicine.49.3532 – volume: 26 start-page: 976 issue: 4 year: 2015 ident: 1806_CR20 publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2014010046 – volume: 51 start-page: 2457 issue: 17 year: 2012 ident: 1806_CR25 publication-title: Intern Med doi: 10.2169/internalmedicine.51.7725 – volume: 83 start-page: 379 issue: 3 year: 1991 ident: 1806_CR41 publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.1991.tb05647.x – volume: 45 start-page: 483 issue: 4 year: 2016 ident: 1806_CR3 publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2015.07.009 – volume: 13 start-page: 313 issue: 3 year: 2014 ident: 1806_CR9 publication-title: Autoimmun Rev doi: 10.1016/j.autrev.2013.11.003 – volume: 95 start-page: e4633 issue: 34 year: 2016 ident: 1806_CR30 publication-title: Medicine doi: 10.1097/MD.0000000000004633 – volume: 51 start-page: 1233 issue: 10 year: 2012 ident: 1806_CR23 publication-title: Intern Med doi: 10.2169/internalmedicine.51.6074 – ident: 1806_CR43 doi: 10.1136/annrheumdis-2011-200612 – volume: 106 start-page: 527 issue: 5 year: 1999 ident: 1806_CR6 publication-title: Am J Med doi: 10.1016/S0002-9343(99)00064-9 – volume: 138 start-page: 183 issue: 1 year: 2004 ident: 1806_CR26 publication-title: Clin Exp Immunol doi: 10.1111/j.1365-2249.2004.02566.x – volume: 135 start-page: 1081 issue: Pt 4 year: 2012 ident: 1806_CR37 publication-title: Brain doi: 10.1093/brain/aws025 – ident: 1806_CR44 doi: 10.1016/j.imlet.2010.06.011 – volume: 70 start-page: 476 issue: 6 year: 2017 ident: 1806_CR1 publication-title: J Clin Pathol doi: 10.1136/jclinpath-2016-203875 – ident: 1806_CR14 – volume: 11 start-page: e0156800 issue: 6 year: 2016 ident: 1806_CR38 publication-title: PLoS One doi: 10.1371/journal.pone.0156800 – volume: 16 start-page: 45 issue: 6 year: 2016 ident: 1806_CR33 publication-title: Curr Allergy Asthma Rep doi: 10.1007/s11882-016-0621-x – volume: 133 start-page: 10302 issue: 26 year: 2011 ident: 1806_CR35 publication-title: J Am Chem Soc doi: 10.1021/ja203638y – volume: 15 start-page: 348 issue: 8 year: 2013 ident: 1806_CR15 publication-title: Curr Rheumatol Rep doi: 10.1007/s11926-013-0348-9 – volume: 339 start-page: 62 issue: 1 year: 2003 ident: 1806_CR22 publication-title: Neurosci Lett doi: 10.1016/S0304-3940(02)01423-4 – volume: 57 start-page: 2390 issue: 6 year: 2013 ident: 1806_CR18 publication-title: Hepatology doi: 10.1002/hep.26232 – volume: 105 start-page: 9 issue: 1 year: 2002 ident: 1806_CR34 publication-title: Immunology doi: 10.1046/j.0019-2805.2001.01341.x – volume: 71 start-page: 390 issue: 3 year: 2012 ident: 1806_CR12 publication-title: Ann Rheum Dis doi: 10.1136/ard.2011.155382 – volume: 9 start-page: 547 issue: 4 year: 2016 ident: 1806_CR4 publication-title: Clin Kidney J doi: 10.1093/ckj/sfw056 – volume: 4 start-page: e341 issue: 3 year: 2017 ident: 1806_CR31 publication-title: Neurol Neuroimmunol Neuroinflamm doi: 10.1212/NXI.0000000000000341 – volume: 87 start-page: 671 issue: 11 year: 1994 ident: 1806_CR10 publication-title: QJM – volume: 64 start-page: 501 issue: 2 year: 2016 ident: 1806_CR19 publication-title: Hepatology doi: 10.1002/hep.28568 – volume: 44 start-page: 2432 issue: 11 year: 2013 ident: 1806_CR13 publication-title: Hum Pathol doi: 10.1016/j.humpath.2013.05.023 – volume: 20 start-page: 92 year: 2017 ident: 1806_CR29 publication-title: Respir Med Case Rep doi: 10.1016/j.rmcr.2017.01.001 – volume: 196 start-page: 2041 issue: 5 year: 2016 ident: 1806_CR39 publication-title: J Immunol doi: 10.4049/jimmunol.1502233 – volume: 45 start-page: 724 issue: 6 year: 2006 ident: 1806_CR7 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kei272 – volume: 70 start-page: 32 issue: 1 year: 1994 ident: 1806_CR40 publication-title: Clin Immunol Immunopathol doi: 10.1006/clin.1994.1007 – ident: 1806_CR42 doi: 10.3389/fimmu.2019.02221 – volume: 26 start-page: S94 issue: 5 Suppl 51 year: 2008 ident: 1806_CR2 publication-title: Clin Exp Rheumatol – volume: 26 start-page: 24 issue: 1 year: 2014 ident: 1806_CR5 publication-title: Curr Opin Rheumatol doi: 10.1097/BOR.0000000000000009 – volume: 44 start-page: 912 issue: 4 year: 2001 ident: 1806_CR11 publication-title: Arthritis Rheum doi: 10.1002/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5 – volume: 54 start-page: 1936 issue: 10 year: 2015 ident: 1806_CR27 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kev248 – volume: 18 start-page: 722 issue: 5 year: 2015 ident: 1806_CR24 publication-title: Pituitary doi: 10.1007/s11102-015-0650-9 – volume: 33 start-page: S-138–41 issue: 2 Suppl 89 year: 2015 ident: 1806_CR16 publication-title: Clin Exp Rheumatol |
| SSID | ssj0022924 |
| Score | 2.311206 |
| Snippet | An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4
) B cells and... Objectives An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4.sup.+) B... An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4.sup.+) B cells and... Objectives An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4+) B... An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive (IgG4+) B cells and... Abstract Objectives An important limitation in granulomatosis with polyangiitis (GPA) is the lack of disease activity markers. Immunoglobulin G4-positive... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 43 |
| SubjectTerms | Adult Aged Antibodies, Antineutrophil Cytoplasmic - blood Antibodies, Antineutrophil Cytoplasmic - immunology Antigens Arthritis B-Lymphocytes - immunology B-Lymphocytes - metabolism Biomarkers Biomarkers - blood Care and treatment Cloning Cross-Sectional Studies Diagnosis Diagnosis, Differential Disease activity Female Granulomatosis with polyangiitis Granulomatosis with Polyangiitis - diagnosis Granulomatosis with Polyangiitis - genetics Granulomatosis with Polyangiitis - immunology Humans Immunoglobulin G - blood Immunoglobulin G - genetics Immunoglobulin G - immunology Immunoglobulin G4 Immunoglobulins Inflammatory diseases Longitudinal Studies Male Middle Aged Mortality Myeloblastin - immunology Myeloblastin - metabolism Neutrophils Observational studies Pathogenesis Patients Plasma Cells - immunology Plasma Cells - metabolism Polymerase chain reaction Quantitative polymerase chain reaction Remission (Medicine) Remission, Spontaneous RNA - blood RNA - genetics RNA - immunology Vein & artery diseases Wegener's granulomatosis Young Adult |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yD-KL-O3qKSMIglCu3aRNei-yiucp3D2IB_cW8tV1YW2P7e6D_5N_pDNptmwR9MWXfWjSbNKZzvymmfyGsddWBcfRrWQh1CYTPq8z5ZzNVMON5b5SvKGDwheX1fmV-HJdXh-U-qKcsIEeeHhwJ7VsHDehlA06z0Y6U1nhXDXPvXMy9_GYL_q8fTCVQq05hhVpD7NQ1UmPllpSkhpGTApD6GrihSJZ_58m-cAnTfMlDxzQ2T12NyFHWAwzvs9uhfYBu32R9sYfsl-fl5_EKf7A18sFRMHCvvwJvsYIKcFE4wZpUwboaAlsqOAbfTKDVQtL9Fy7dYcotutXPdBHWrjp1j9Nu1wR-dEpGEAcPo4QB0QcDz8oy2fzDhYQF5z1McOL5mtaD-uOqiLtPFXggkho-4hdnX389uE8S7UYMoeYaJsVtQq8MaUtPAIa7r0py1J6yS1XlnYPS5mb2klZeDQRDUalKswNL5pacIQ4nj9mR23XhqcMTG19bnEg65xw1pnSm2DmShlZ2NqGGcv3stEuEZVTvYy1jgGLqvQgTo3i1CROXc3Y2_GWm4Gl42-d35PAx45EsB0voNrppHb6X2o3Y29IXTSZAZycM-k0Ay6RCLX0olQFF6UU9YwdT3qiUN20ea9wOpmPXhNuRWSqcvyfV2Mz3UkpcW3odtQHTSlVG8A-Twb9HJdEhlwg0p8xOdHcyZqnLe3qeyQXJ35Cwfmz__GQnrM7iC8pHw9d_TE72m524QViuK19GV_X3x4nSPc priority: 102 providerName: Directory of Open Access Journals |
| Title | IgG4:IgG RNA ratio differentiates active disease from remission in granulomatosis with polyangiitis: a new disease activity marker? A cross-sectional and longitudinal study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30704507 https://www.proquest.com/docview/2183056808 https://www.proquest.com/docview/2179473008 https://pubmed.ncbi.nlm.nih.gov/PMC6357433 https://doaj.org/article/97fc3ae57f064f7ca6b4cc620dcc70d8 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBdbC2MvY9_z1gUNBoOBqR3JltyXko523aBhlAXyJvTlNJDZWZw87H_aH7k7RUlrBn3xg_WBxJ3ufnc63RHy0UhvGaiV1PtKp9xlVSqtNamsmTbMlZLV-FD4alxeTvj3aTGNDrcuhlXuZGIQ1K616CM_RlUOylpm8nT5O8WqUXi7GktoPCSHmLoMuVpMbw2uYbUtasvBUgLFyuOtZi7L4w5kt8CwNbChJBjVZU8vhfT9_wvpO1qqH0F5RyVdPCVPIpakoy3xn5EHvnlOHl3F2_IX5O-32Vd-Ah96PR7RQGq6K4gCBxtAJtVB3NF4TUPxsQldYQk4dKLReUNnoMs2ixZwbdvNO4puW7psF390M5tjOqQTqikg8_0MYUJA9vQXxv2sTumIhg2nXYj5wvXqxtFFi3WSNg5rctGQ4vYlmVyc__xymcbqDKkFlLRO80p6VuvC5A4gDnNOF0UhnGCGSYP3iYXIdGWFyB0IjRrsVOmHmuV1xRmAHsdekYOmbfwbQnVlXGZgImMtt8bqwmmvh1JqkZvK-IRkO9ooG1OXYwWNhQomjCzVlpwKyKmQnKpMyOf9kOU2b8d9nc-Q4PuOmHI7_GhXMxVPsKpEbZn2hagBxdXC6tJwa8th5qwVmZMJ-YTsolAwwOKsju8bYIuYYkuNCpkzXgheJeSo1xOIavvNO4ZTUaB06pb9E_Jh34wjMUiu8e0G-4BwxfoD0Of1lj_3W0LRzgH7J0T0OLe3535LM78J6cYxYyFn7O39y3pHHgOWxNg7UOtH5GC92vj3gNfWZhAO5YAcnp2Pf1wPgtcDvpPh6B8dU0ST |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkYAL4k2ggJFASEhRkziJnUqoWh5ll3b3gFqpN9evLCstybLZFep_QvxGZvLYNkLqrZccYseyNZP55rPHM4S80cIZBrDiO5cpP7ZB5gtjtC9ypjSzqWA5XhQeT9LhSfztNDndIn-7uzAYVtnZxNpQ29LgHvkuQjmAtQjE_uKXj1Wj8HS1K6HRqMWhO_8NlK36MPoM8n0bRQdfjj8N_baqgG8A3Vc-sGzHcpXo0AI0M2tVkiTccqaZ0HgOlvBAZYbz0IKy58CvhIsUC_MsZgDWlsG4N8hNAN4AyR4_vSB4UdYU0Y2BmQGQx-0paijS3QqwgmOYHHA2ASQ-7eFgXS7gf1C4hIr9iM1LEHhwj9xtfVc6aJTtPtlyxQNya9yezj8kf0bTr_EePOj3yYDWqkW7AixgSMCppao2r7Q9FqJ4uYUuseQcbtrRWUGngJ3reQl-dFnNKorbxHRRzs9VMZ1h-qU9qigwgc0I9YDAJOhPjDNa7tMBrRfsV3WMGc5XFZbOS6zLtLZYA4zWKXUfkZNrkdtjsl2UhXtKqMq0DTQMpI2JjTYqscqpSAjFQ51p55Ggk400bap0rNgxlzVlEqlsxClBnBLFKVOPvN98smjyhFzV-SMKfNMRU3zXL8rlVLYWQ2Y8N0y5hOfgNebcqFTHxqRRYI3hgRUeeYfqItEQweSMau9TwBIxpZccJCJkccLjzCM7vZ4gVNNv7hROtgaskhe_m0deb5rxSwzKK1y5xj5gzLHeAfR50ujnZkkIJTFwDY_wnub21txvKWY_6vTmmCExZuzZ1dN6RW4Pj8dH8mg0OXxO7oAfi3F_4FLskO3Vcu1egK-40i_rH5SSs-u2CP8Af1d75A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=IgG4%3AIgG+RNA+ratio+differentiates+active+disease+from+remission+in+granulomatosis+with+polyangiitis%3A+a+new+disease+activity+marker%3F+A+cross-sectional+and+longitudinal+study&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Al-Soudi%2C+A&rft.au=Doorenspleet%2C+M+E&rft.au=Esveldt%2C+R+E&rft.au=Burgemeister%2C+L+T&rft.date=2019-01-31&rft.pub=BioMed+Central&rft.issn=1478-6354&rft.eissn=1478-6362&rft.volume=21&rft_id=info:doi/10.1186%2Fs13075-018-1806-6 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6362&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6362&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6362&client=summon |